S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:OPRX

OptimizeRx Earnings Date, Estimates, & History

$49.68
-1.76 (-3.42%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.14
$51.90
50-Day Range
$49.68
$93.37
52-Week Range
$38.74
$99.18
Volume
334,790 shs
Average Volume
261,719 shs
Market Capitalization
$882.81 million
P/E Ratio
354.86
Dividend Yield
N/A
Beta
0.55

Earnings Summary

Upcoming
Earnings Date
Feb. 23
Estimated

Actual EPS
(Nov. 9)
$0.09
Missed By -$0.04

Consensus EPS
(Nov. 9)
$0.13

Last Year's Q4 EPS
(11/9/2020)
-$0.01

Skip Charts & View Estimated and Actual Earnings Data

OptimizeRx Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

OptimizeRx Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

OptimizeRx (NASDAQ:OPRX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20221$0.11$0.11$0.11 
Q2 20221$0.16$0.16$0.16 
Q3 20221$0.24$0.24$0.24 
Q4 20221$0.54$0.54$0.54 
FY 20224$1.05$1.05$1.05

OPRX Earnings Information

OptimizeRx last released its earnings results on November 9th, 2021. The reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.04. The business earned $16.13 million during the quarter, compared to analysts' expectations of $14.82 million. OptimizeRx has generated $0.14 earnings per share over the last year ($0.14 diluted earnings per share) and currently has a price-to-earnings ratio of 354.9. Earnings for OptimizeRx are expected to grow by 168.75% in the coming year, from $0.16 to $0.43 per share. OptimizeRx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 23rd, 2022 based off prior year's report dates.

OptimizeRx (NASDAQ:OPRX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
2/23/2022
(Estimated)
        
11/9/20219/30/2021$0.13$0.09($0.04)$14.82 million$16.13 million    
8/4/20216/30/2021$0.02$0.10+$0.08$0.02$12.35 million$13.63 million    
5/6/2021Q1 2021($0.03)($0.01)+$0.02($0.06)$10.32 million$11.23 million
2/23/202112/31/2020$0.16$0.16$0.14$16.02 million$16.43 million  
11/9/2020Q3 2020($0.02)($0.01)+$0.01$10.04 million$10.52 million  
8/5/20206/30/2020($0.03)$0.02+$0.05($0.07)$8.02 million$8.78 million  
5/4/20203/31/2020($0.03)($0.06)($0.03)($0.15)$7.10 million$7.59 million  
2/27/2020Q4 2019($0.05)($0.03)+$0.02($0.06)$7.66 million$7.38 million  
11/5/2019Q3$0.04($0.11)($0.15)($0.11)$7.21 million$5.00 million  
8/7/2019Q2 2019$0.03$0.03$0.03$6.78 million$7.01 million
11/5/2018Q3 2018$0.01$0.02+$0.01$0.02$5.28 million$5.42 million
11/5/2018Q3$0.01$0.02+$0.01$0.02$5.28 million$5.42 million
8/7/2018Q2 2018($0.02)$0.02+$0.04$0.02$4.34 million$5.10 million
8/7/2018Q2 2018$0.02$0.02$0.02$4.34 million$5.10 million
5/2/2018Q1 2018($0.03)($0.03)($0.03)$4.11 million
5/2/2018Q1 2018($0.03)($0.03)($0.03)$4.11 million
2/27/2018Q4 2017($0.03)($0.03)($0.03)$4.01 million
2/27/2018Q4 2017($0.01)($0.01)($0.01)$4.01 million
11/2/2017Q3 2017($0.06)($0.06)($0.06)$3.10 million
11/2/2017Q3 2017($0.02)($0.02)($0.02)$3.10 million
8/1/2017Q2 2017($0.03)($0.03)($0.03)$2.87 million
8/1/2017Q2 2017($0.01)($0.01)($0.01)$2.87 million  
5/3/2017Q1 2017($0.09)($0.09)($0.09)$2.15 million
5/3/2017Q1 2017($0.03)($0.03)($0.03)$2.15 million  
3/8/2017Q4 2016($0.03)($0.03)($0.03)$2.29 million
3/8/2017Q4 2016($0.01)($0.01)($0.01)$2.29 million
11/7/2016Q3 2016($0.03)($0.03)($0.03)$1.79 million
11/7/2016Q3 2016($0.01)($0.01)($0.01)$1.79 million
8/8/2016Q2 2016($0.06)($0.06)($0.06)$2.05 million$1.91 million
8/8/2016Q2 2016($0.02)($0.02)($0.02)$2.05 million$1.91 million
5/9/2016Q1 2016($0.09)($0.03)+$0.06($0.03)$1.70 million$1.76 million
5/9/2016Q1 2016($0.09)($0.03)+$0.06($0.03)$1.70 million$1.76 million
3/15/2016Q4 2015($0.03)($0.03)($0.03)$2.30 million$2.02 million
3/15/2016Q4 2015($0.03)($0.03)($0.03)$2.30 million$2.02 million
8/11/2015Q2 2015($0.03)($0.03)($0.03)$1.92 million$1.71 million
8/11/2015Q2 2015($0.01)($0.01)($0.01)$1.92 million$1.71 million
3/31/2015Q4 2014$0.03$0.03$0.03$1.92 million$1.97 million
3/31/2015Q4 2014$0.03$0.03$0.03$1.92 million$1.97 million
11/13/2014Q3 2014($0.06)($0.06)($0.06)$1.71 million$1.62 million
11/13/2014Q3 2014($0.06)($0.06)($0.06)$1.71 million$1.62 million  
5/16/2014Q1 2014$0.03($0.12)($0.15)($0.12)$1.92 million$1.32 million
5/16/2014Q1 2014$0.03($0.12)($0.15)($0.12)$1.92 million$1.32 million
8/12/2013Q2 2013$0.06$0.03($0.03)$0.03$1.10 million$1.10 million
8/12/2013Q2 2013$0.02$0.01($0.01)$0.01$1.10 million$1.10 million
3/12/2013Q4 2012$0.01$0.01$0.01
5/15/2012Q1 2012($0.03)($0.02)+$0.01($0.02)
(Earnings results data provided by Zacks Investment Research)












OptimizeRx (NASDAQ:OPRX) Earnings Frequently Asked Questions

When is OptimizeRx's earnings date?

OptimizeRx has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 23rd, 2022 based off last year's report dates. Learn more on OPRX's earnings history

Did OptimizeRx beat their earnings estimates last quarter?

In the previous quarter, OptimizeRx (NASDAQ:OPRX) missed the analysts' consensus estimate of $0.13 by $0.04 with a reported earnings per share (EPS) of $0.09. Learn more on OPRX's earnings details

How can I listen to OptimizeRx's earnings conference call?

The conference call for OptimizeRx's latest earnings report can be listened to online. Listen to Conference Call

How can I read OptimizeRx's conference call transcript?

The conference call transcript for OptimizeRx's latest earnings report can be read online. Read Transcript

How much revenue does OptimizeRx generate each year?

OptimizeRx (NASDAQ:OPRX) has a recorded annual revenue of $43.31 million.

How much profit does OptimizeRx generate each year?

OptimizeRx (NASDAQ:OPRX) has a recorded net income of -$2.21 million. OPRX has generated $0.14 earnings per share over the last four quarters.

What is OptimizeRx's price-to-earnings ratio?

OptimizeRx (NASDAQ:OPRX) has a trailing price-to-earnings ratio of 354.86 and a forward price-to-earnings ratio of 310.50.

What is OptimizeRx's EPS forecast for next year?

OptimizeRx's earnings are expected to grow from $0.16 per share to $0.43 per share in the next year, which is a 168.75% increase.

This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.